Sintilimab Enhances AP Regimen for Cancer

The patients were divided into an observation group treated with sintilimab injection and the AP regimen (n = 16) and a control group treated with the AP regimen only (n = 16). Both groups received the AP regimen, which consisted of intravenous injection of 25 mg/m² doxorubicin on days 1–3 and 100 mg/m² of cisplatin by intravenous drip for 24 hours on day two, with each cycle lasting 21 days. Both groups of patients were treated for six cycles. The observation group was also administered 200 mg of sintilimab by intravenous drip every three weeks on the first day of chemotherapy.